[updated February 24, 1999]

 
 

Table 2. Cardiovascular outcomes by treatment group*


 
          Treatment Group          

Outcomes
Estrogen-Progestin (n=1380)
Placebo
(n=1383)
RH (95% CI)
P Value
Primary CHD events†
179
182
0.99 (0.81-1.22)
0.94
   CHD death
  70
  59
1.20 (0.85-1.69)
0.31
   Nonfatal MI
122
134
0.92 (0.72-1.17)
0.50
Other Cardiovascular Outcomes        
   Coronary artery bypass surgery
  92
105
0.88 (0.66-1.16)
0.36
   Percutaneous coronary revascularization
175
182
0.97 (0.79-1.19)
0.77
   Hospitalization for unstable angina
109
120
0.91 (0.70-1.18)
0.47
   Hospitalization for congestive heart failure
132
128
1.04 (0.82-1.33)
0.74
   Resuscitated cardiac arrest
  20
  13
1.56 (0.77-3.13)
0.21
   Other CHD event
    3
    1
3.03 (0.32-29.1)
0.34
   Peripherial arterial disease
100
116
0.86 (0.66-1.13)
0.28
   Stroke/transient ischemic attack
112
103
1.08 (0.83-1.42)
0.55


* RH indicates relative hazard; CI, confidence interval; CHD, coronary heart disease; and MI, myocardio infarction.
Each row represents the number of women with the designated event; women with more than 1 type of event may appear
in more than 1 row.
† Primary CHD events include coronary death and nonfatal MI. Among the 256 nonfatal MIs, there were 11 silent MIs,
found on annual electrocardiogram. There were 24 women with nonfatal myocardial infarction who subsequently
suffered CHD death.